| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2012/01/03 | 22 : 00 | Marketwired | Poniard Pharmaceuticals Common Stock to Be Delisted From Nasdaq Stock Market, Intention to List on OTC Bulletin Board | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/12/24 | 05 : 37 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/23 | 04 : 13 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/22 | 03 : 15 | Marketwired | Poniard Pharmaceuticals Announces Shareholders Approve Merger With ALLOZYNE | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/21 | 23 : 00 | Marketwired | Steps in the Right Direction - Featured Research on Poniard Pharmaceuticals, Inc. and Gilead Sciences, Inc. | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/19 | 03 : 00 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/18 | 22 : 30 | Marketwired | Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/11 | 04 : 54 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/10 | 03 : 16 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/09 | 22 : 30 | Marketwired | ISS Proxy Advisory Services Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse St... | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/08 | 20 : 05 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/07 | 22 : 30 | Marketwired | Glass Lewis Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/04 | 19 : 10 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(3) (424B3) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/11/03 | 05 : 01 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/29 | 05 : 16 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/29 | 05 : 01 | Marketwired | Poniard Pharmaceuticals Reports Third Quarter 2011 Financial Results | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/29 | 02 : 59 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/29 | 00 : 19 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/28 | 21 : 30 | Marketwired | Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/25 | 04 : 47 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/22 | 03 : 00 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (DEFA14A) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/13 | 02 : 43 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/13 | 02 : 41 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/13 | 02 : 37 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(3) (424B3) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/11 | 22 : 10 | Dow Jones News | Registration Effectiveness Orders Issued By The SEC | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/11 | 19 : 00 | Edgar (US Regulatory) | Notice of Effectiveness (EFFECT) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/08 | 06 : 43 | Marketwired | Poniard Pharmaceuticals Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with ALLOZYNE | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/08 | 06 : 27 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/08 | 06 : 26 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 2011/10/08 | 02 : 22 | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |